PHOENIX, February 16, 2021 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, today announced that Steve Potts, Ph.D., MBA, cofounder and chief executive officer of OncoMyx, will present at the BIO CEO & Digital Conference, available online February 16-18, 2021. OncoMyx’s presentation will be accessible on demand during the virtual event for all registered attendees.
Event registration is available at https://www.bio.org/events/bio-ceo-investor-digital-conference.
About OncoMyx Therapeutics
OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response to better treat cancer. Successful immuno-oncology (IO) cancer treatment generally requires combination therapy, and oncolytic viruses (OVs) have the potential to be a safe and effective complement to immunotherapies. The company’s MYXV platform, exclusively licensed from Arizona State University and Western, is poised to be a best-in-class OV approach, and the top OV team has assembled around MYXV to create important new therapeutic options for cancer patients.